Voyager Therapeutics Presents New Preclinical Data Showing Reduction of Pathological Tau with Vectorized Anti-Tau Antibody
May 12 2021 - 7:30AM
Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage
gene therapy company focused on developing life-changing treatments
for serious neurological diseases today will present new
preclinical data characterizing the durable expression and activity
of a vectorized anti-tau antibody at the 24th Annual Meeting
of the American Society of Gene and Cell
Therapy (ASGCT), taking place virtually May 11-14, 2021.
“Tauopathies such as progressive supranuclear palsy, frontal
temporal dementia, and Alzheimer’s disease are devastating
neurodegenerative disorders, and we believe that our novel
vectorized anti-tau antibody approach holds the promise to deliver
more therapeutically relevant antibodies directly to critical brain
regions associated with disease progression,” said Kelly Bales,
Ph.D., Senior Vice President of Neuroscience at Voyager. “By
directing CNS-targeted AAV vectors to encode a novel anti-tau
monoclonal antibody, our approach has the potential to improve the
efficacy and durability of anti-tau immunotherapies.”
Voyager has developed modular antibody vectorization cassettes,
which consist of an adeno-associated virus (AAV) vector and a
transgene encoding anti-tau monoclonal full-length antibodies.
Following intravenous (IV) administration and transduction of
target cells in the brain, the expressed antibodies are
functionally reconstituted and subsequentially secreted into the
parenchyma.
In an oral presentation titled “Efficacy of a Vectorized
Anti-Tau Antibody Using Systemic Dosing of a Blood Brain
Penetrant AAV Capsid in Mouse Models of Tauopathies,” (Abstract
#105), Principal Scientist Wencheng Liu, Ph.D., will present data
demonstrating promoter-driven, cell-specific expression of a
vectorized anti-tau antibody and efficacy in multiple tauopathy
mouse models.
- Anti-tau antibody expression was detected as early as 2 days
post-dose, reaching maximum levels at day 7, with durable
expression extending to 28 days following IV administration of
vectorized anti-tau antibody to rodents.
- Dose-dependent decreases in the levels of pathological tau and
neurofibrillary tangles were observed following IV administration
of a vectorized anti-tau antibody to a rodent tauopathy model,
resulting in up to 59% reduction in tau pathology.
The company will host a virtual investor and analyst event in
July, 2021 to share more about its novel TRACER™ capsids, its
anti-tau vectorized antibody program, and other pipeline and
platform developments.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy
company focused on developing life-changing treatments for serious
neurological diseases. Voyager is committed to advancing the field
of AAV gene therapy through innovation and investment in vector
engineering and optimization, manufacturing, and dosing and
delivery techniques. For more information on Voyager
Therapeutics, please visit the company’s website
at www.voyagertherapeutics.com or
follow @VoyagerTx on Twitter and LinkedIn.
Voyager Therapeutics® is a registered trademark, and TRACER™ is
a trademark, of Voyager Therapeutics, Inc.
Forward-Looking Statements
This press release contains forward-looking statements
for the purposes of the safe harbor provisions under The Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as “may,” “might,” “will,”
“would,” “should,” “expect,” “plan,” “anticipate,” “believe,”
“estimate,” “undoubtedly,” “project,” “intend,” “future,”
“potential,” or “continue,” and other similar expressions are
intended to identify forward-looking statements. For
example, all statements Voyager makes regarding anti-tau
immunotherapy as a promising therapeutic approach; the potential
ability of anti-tau immunotherapy to address multiple CNS diseases;
and potential ability of anti-tau immunotherapy to improve the
effectiveness of antibody immunotherapy are forward looking.
All forward-looking statements are based on estimates and
assumptions by Voyager’s management that, although Voyager believes
such forward-looking statements to be reasonable, are inherently
uncertain. All forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those that Voyager expected. Such risks and uncertainties
include, among others the severity and length of the COVID-19
health crisis; the initiation and conduct of preclinical studies
involving our vectorized anti-tau antibody program; the continued
development of Voyager’s gene therapy platform and Voyager’s TRACER
system; the applicability of novel capsids identified by the TRACER
system to the vectorized anti-tau antibody program; Voyager’s
scientific approach and general development progress; the ability
to attract and retain highly skilled and experienced
scientists and technicians; the ability to create and protect
intellectual property related to Voyager’s vectorized anti-tau
antibody program and development of novel capsids; and the
availability of resources necessary to conduct the gene therapy
development programs, including access to sufficient number and
types of primates suitable for participation in ongoing and planned
preclinical research activities.
These statements are also subject to a number of material risks
and uncertainties that are described in Voyager’s Annual Report on
Form 10-K for the year ended December 31, 2020 filed with
the Securities and Exchange Commission, as updated by its
subsequent filings with the Securities and Exchange
Commission. All information in the press release is as of the date
of this press release, and any forward-looking statement speaks
only as of the date on which it was made. Voyager undertakes no
obligation to publicly update or revise this information or any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
Investor
Inquiries:investors@voyagertherapeutics.com
Media Inquiries:Lissette SteeleVerge Scientific
Communications202.930.4762 x 409lsteele@vergescientific.com
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Voyager Therapeutics (NASDAQ:VYGR)
Historical Stock Chart
From Sep 2023 to Sep 2024